---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-128616"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:10:38.819033+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics reports positive Phase 2a data for bexotegrast in IPF; FVC decline reduced 68% vs placebo

## Summary
- Bexotegrast 320 mg well tolerated up to 40 weeks; no drug-related serious adverse events.
- FVC decline reduced 68% vs placebo: mean FVCpp change -0.8% vs -2.5% at Week 24.
- 89% of patients with FVC increase at Week 12 maintained increase through Week 24.
- QLF imaging showed fibrosis stabilization in bexotegrast group vs progression in placebo.
- BEACON-IPF Phase 2b trial (160/320 mg, ~270 patients) to initiate in mid-2023.

## SEC filing metadata
- accession: 0001193125-23-128616
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312523128616/0001193125-23-128616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312523128616/d440511d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-128616
- JSON: https://secwatch.observer/filing/0001193125-23-128616.json
- Plain text: https://secwatch.observer/filing/0001193125-23-128616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.